Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing (METFORGENE)
Effect of Treatment With Metformin in Type 2 Diabetes Patients on Alternative Genes Splicing Whose Maturation Depends on the Protein HuR, Including Gene Encoding Insulin Receptor
Sponsor: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Listed as NCT01349387, this NA trial focuses on Type 2 Diabetes and remains completed. Sponsored by Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Sep 2020 — Jan 2021 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
For direct contact, visit the study record on ClinicalTrials.gov .